Biology subjects

Saez-Rodriguez, J.

Publications and source records attributed to Saez-Rodriguez, J..

At least 91 records · Page 5Linked to original sources

bioRxiv2020

A Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile Data

The Columbia Cancer Target Discovery and Development (CTD2) Center has developed PANACEA (PANcancer Analysis of Chemical Entity Activity), a collection of dose-response curves and perturbational profiles for 400 clinical oncology drugs in cell lines selected to optimally represent 19 cancer subtypes. This resource, developed to study tumor-specific drug mechanism of action, was instrumental in hosting a DREAM Challenge to assess computational models for de novo drug polypharmacology prediction. Dose-response and perturbational profiles for 32 kinase inhibitors were provided to 21 participating teams, who did not know the identity or nature of the compounds, and they were asked to predict high-affinity binding among ~1,300 possible protein targets. Best performing methods leveraged both gene expression profile similarity analysis, and deep-learning methodologies trained on individual datasets. This study lays the foundation for future integrative analyses of pharmacogenomic data, reconciliation of polypharmacology effects in different tumor contexts, and insights into network-based assessment of context-specific drug mechanism of action.

cancer biology↗

bioRxiv2020

Integrated intra- and intercellular signaling knowledge for multicelullar omics analysis

Molecular knowledge of biological processes is a cornerstone in the analysis of omics data. Applied to single-cell data, such analyses can provide mechanistic insights into individual cells and their interactions. However, knowledge of intercellular communication is scarce, scattered across different resources, and not linked to intracellular processes. To address this gap, we combined over 100 resources in a single database. It covers the interactions and roles of proteins in inter- and intracellular signal transduction, as well as transcriptional and post-transcriptional regulation. We also provide a comprehensive collection of protein complexes and rich annotations on the properties of proteins, including function, localization, and role in diseases. The resource is available for human, and via homology translation for mouse and rat. The data is accessible via OmniPaths web service, a Cytoscape plugin, and packages in R/Bioconductor and Python, providing convenient access options for both computational and experimental scientists. Our resource provides a single access point to knowledge spanning intra- and intercellular processes for data analysis, as we demonstrate in applications to study SARS-CoV-2 infection and ulcerative colitis. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=92 SRC="FIGDIR/small/221242v2_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@15de883org.highwire.dtl.DTLVardef@4bfb6aorg.highwire.dtl.DTLVardef@67113aorg.highwire.dtl.DTLVardef@9c328a_HPS_FORMAT_FIGEXP M_FIG C_FIG

systems biology↗

bioRxiv2020

Why do pathway methods work better than they should?

Different pathway analysis methods are frequently applied to cancer gene expression data to identify dysregulated pathways. In most cases these methods infer pathway activity changes based on the gene expression of pathway members. However, pathways are constituted by signaling proteins, and their activity - not their abundance - defines the activity of the pathway; the association between gene expression and protein activity is in turn limited and not well characterised. Other methods infer pathway activity from the expression of the genes whose transcription is regulated by the pathway of interest, which seems a more adequate proxy of activity. Despite these potential limitations, membership based pathway methods are frequently used and often provide statistically significant results. Here, we submit that pathway based methods are not effective because of the correlation between the gene expression of pathway members and the activity of the pathway, but because pathway member gene sets overlap with the genes regulated by transcription factors (regulons). This implies that pathway methods do not inform about the activity of the pathway of interest, but instead the downstream effects of changes in the activities of transcription factors. To support our hypothesis, we show that the higher the overlap to transcription factor regulons, the higher the information value of pathway gene sets. Furthermore, removing these overlapping genes reduces the information content of pathway gene sets, but not vice versa. Our results suggest that results of classical pathway analysis methods should be interpreted with caution, and instead methods using pathway regulated genes for activity inference should be prioritised. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=129 SRC="FIGDIR/small/228296v1_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@f955baorg.highwire.dtl.DTLVardef@16b2f0aorg.highwire.dtl.DTLVardef@1dd6b7dorg.highwire.dtl.DTLVardef@1bbfe59_HPS_FORMAT_FIGEXP M_FIG C_FIG

systems biology↗

bioRxiv2020

Metabolic control of tumour extracellular matrix production in cancer-associated fibroblasts

TElevated production of collagen-rich extracellular matrix (ECM) is a hallmark of cancer associated fibroblasts (CAFs) and a central driver of cancer aggressiveness. How to target ECM production to oppose cancer is yet unclear, since targeting CAFs has been shown to restrain but also promote cancer progression. Metabolic rewiring is a hallmark of CAFs. Here we find that proline, which is a highly abundant amino acid in collagen proteins, is newly synthesised from glutamine to make tumour collagen in breast cancer xenografts, and that its production is elevated in breast cancer CAFs. PYCR1 is the rate-limiting enzyme for proline synthesis and is highly expressed in the tumour stroma of breast cancer patients and in CAFs. Reducing PYCR1 levels in CAFs is sufficient to reduce tumour collagen production, tumour growth and metastatic spread in vivo and cancer cell proliferation in vitro. PYCR1 and COL1A1 are overexpressed in patients with invasive ductal carcinoma with poor prognosis. Both collagen and glutamine-derived proline synthesis in CAFs are enhanced by increased pyruvate dehydrogenase-derived acetyl-CoA levels, via gene expression regulation through the epigenetic regulator histone acetyl transferase EP300. Altogether, our work unveils unprecedented roles of CAF metabolism to support pro-tumorigenic collagen production. PYCR1 is a recognised cancer cell vulnerability and potential target for therapy, hence, our work provides evidence that targeting PYCR1 in tumours may have the additional benefit of halting the production of pro-tumorigenic ECM.

cancer biology↗

bioRxiv2020

Explainable multi-view framework for dissecting inter-cellular signaling from highly multiplexed spatial data

The advancement of technologies to measure highly multiplexed spatial data requires the development of scalable methods that can leverage the spatial information. We present MISTy, a flexible, scalable and explainable machine learning framework for extracting interactions from any spatial omics data. MISTy builds multiple views focusing on different spatial or functional contexts to dissect different effects, such as those from direct neighbours versus those from distant cells. MISTy can be applied to different spatially resolved omics data with dozens to thousands of markers, without the need to perform cell-type annotation. We evaluate the performance of MISTy on an in silico dataset and demonstrate its applicability on three breast cancer datasets, two measured by imaging mass cytometry and one by Visium spatial transcriptomics. We show how we can estimate interactions coming from different spatial contexts that we can relate to tumor progression and clinical features. Our analysis also reveals that the estimated interactions in triple negative breast cancer are associated with clinical outcomes which could improve patient stratification. Finally, we demonstrate the flexibility of MISTy to integrate different kinds of views by modeling activities of pathways estimated from gene expression in a spatial context to analyse intercellular signaling.

systems biology↗

bioRxiv2020

A statistical framework for assessing pharmacological response and biomarkers with confidence

Drug high-throughput screenings across large molecular-characterised cancer cell line panels enable the discovery of biomarkers, and thereby, cancer precision medicine. The ability to experimentally generate drug response data has accelerated. However, this data is typically quantified by a summary statistic from a best-fit dose response curve, whilst neglecting the uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the experimental variance using Gaussian Processes, and subsequently, leverage this uncertainty for identifying associated biomarkers with a new statistical framework based on Bayesian testing. Applied to the Genomics of Drug Sensitivity in Cancer, in vitro screening data on 265 compounds across 1,074 cell lines, our uncertainty models identified 24 clinically established drug response biomarkers, and in addition provided evidence for 6 novel biomarkers. We validated our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to drug high-throughput screens without replicates, and enables robust biomarker discovery for new cancer therapies.

cancer biology↗

bioRxiv2020

Causal integration of multi-omics data with prior knowledge to generate mechanistic hypotheses

Multi-omics datasets can provide molecular insights beyond the sum of individual omics. Diverse tools have been recently developed to integrate such datasets, but there are limited strategies to systematically extract mechanistic hypotheses from them. Here, we present COSMOS (Causal Oriented Search of Multi-Omics Space), a method that integrates phosphoproteomics, transcriptomics, and metabolics datasets. COSMOS combines extensive prior knowledge of signaling, metabolic, and gene regulatory networks with computational methods to estimate activities of transcription factors and kinases as well as network-level causal reasoning. COSMOS provides mechanistic hypotheses for experimental observations across multi-omics datasets. We applied COSMOS to a dataset comprising transcriptomics, phosphoproteomics, and metabolomics data from healthy and cancerous tissue from nine renal cell carcinoma patients. We used COSMOS to generate novel hypotheses such as the impact of Androgen Receptor on nucleoside metabolism and the influence of the JAK-STAT pathway on propionyl coenzyme A production. We expect that our freely available method will be broadly useful to extract mechanistic insights from multi-omics studies. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=86 SRC="FIGDIR/small/057893v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@37d2d7org.highwire.dtl.DTLVardef@f333d4org.highwire.dtl.DTLVardef@cfcac3org.highwire.dtl.DTLVardef@90318_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioinformatics↗

bioRxiv2020

Converting networks to predictive logic models from perturbation signalling data with CellNOpt

MotivationThe molecular changes induced by perturbations such as drugs and ligands are highly informative of the intracellular wiring. Our capacity to generate large data-sets is increasing steadily as new experimental approaches are developed. A useful way to extract mechanistic insight from the data is by integrating them with a prior knowledge network of signalling to obtain dynamic models. Logic models scale better with network size than alternative kinetic models, while keeping the interpretation of the model simple, making them particularly suitable for large datasets. ResultsCellNOpt is a collection of Bioconductor R packages for building logic models from perturbation data and prior knowledge of signalling networks. We have recently developed new components and refined the existing ones. These updates include (i) an Integer Linear Programming (ILP) formulation which guarantees efficient optimisation for Boolean models, (ii) a probabilistic logic implementation for semi-quantitative datasets and (iii) the integration of MaBoSS, a stochastic Boolean simulator. Furthermore, we introduce Dynamic-Feeder, a tool to identify missing links not present in the prior knowledge. We have also implemented systematic post-hoc analyses to highlight the key components and parameters of our models. Finally, we provide an R-Shiny tool to run CellNOpt interactively. AvailabilityR-package(s): https://github.com/saezlab/cellnopt Contactjulio.saez@bioquant.uni-heidelberg.de Supplementary informationSupplemental Text.

bioinformatics↗

bioRxiv2020

Deciphering the Signaling Network Landscape of Breast Cancer Improves Drug Sensitivity Prediction

Although genetic and epigenetic abnormalities in breast cancer have been extensively studied, it remains difficult to identify those patients who will respond to particular therapies. This is due in part to our lack of understanding of how the variability of cellular signaling affects drug sensitivity. Here, we used mass cytometry to characterize the single-cell signaling landscapes of 62 breast cancer cell lines and five lines from healthy tissue. We quantified 34 markers in each cell line upon stimulation by the growth factor EGF in the presence or absence of five kinase inhibitors. These data - on more than 80 million single cells from 4,000 conditions - were used to fit mechanistic signaling network models that provide unprecedented insights into the biological principles of how cancer cells process information. Our dynamic single-cell-based models more accurately predicted drug sensitivity than static bulk measurements for drugs targeting the PI3K-MTOR signaling pathway. Finally, we identified genomic features associated with drug sensitivity by using signaling phenotypes as proxies, including a missense mutation in DDIT3 predictive of PI3K-inhibition sensitivity. This provides proof of principle that single-cell measurements and modeling could inform matching of patients with appropriate treatments in the future. One-linerSingle-cell proteomics coupled to perturbations improves accuracy of breast tumor drug sensitivity predictions and reveals mechanisms of sensitivity and resistance. HIGHLIGHTSO_LIMass cytometry study of signaling responses of 62 breast cancer cell lines and five lines from healthy tissue to EGF stimulation with or without perturbation with five kinase inhibitors. C_LIO_LISingle-cell signaling features and mechanistic signaling network models predicted drug sensitivity. C_LIO_LIMechanistic signaling network models deepen the understanding of drug resistance and sensitivity mechanisms. C_LIO_LIWe identify drug sensitivity-predictive genomic features via proxy signaling phenotypes. C_LI

systems biology↗

bioRxiv2019

Predicting cellular position in the Drosophila embryo from Single-Cell Transcriptomics data

Single-cell RNA-seq technologies are rapidly evolving but while very informative, in standard scRNAseq experiments the spatial organization of the cells in the tissue of origin is lost. Conversely, spatial RNA-seq technologies designed to keep the localization of the cells have limited throughput and gene coverage. Mapping scRNAseq to genes with spatial information increases coverage while providing spatial location. However, methods to perform such mapping have not yet been benchmarked. To bridge the gap, we organized the DREAM Single-Cell Transcriptomics challenge focused on the spatial reconstruction of cells from the Drosophila embryo from scRNAseq data, leveraging as gold standard genes with in situ hybridization data from the Berkeley Drosophila Transcription Network Project reference atlas. The 34 participating teams used diverse algorithms for gene selection and location prediction, while being able to correctly localize rare subpopulations of cells. Selection of predictor genes was essential for this task and such genes showed a relatively high expression entropy, high spatial clustering and the presence of prominent developmental genes such as gap and pair-ruled genes and tissue defining markers.

systems biology↗

bioRxiv2019

Robustness and applicability of functional genomics tools on scRNA-seq data

Many tools have been developed to extract functional and mechanistic insight from bulk transcriptome profiling data. With the advent of single-cell RNA sequencing (scRNA-seq), it is in principle possible to do such an analysis for single cells. However, scRNA-seq data has characteristics such as drop-out events, low library sizes and a comparatively large number of samples/cells. It is thus not clear if functional genomics tools established for bulk sequencing can be applied to scRNA-seq in a meaningful way. To address this question, we performed benchmark studies on in silico and in vitro single-cell RNA-seq data. We included the bulk-RNA tools PROGENy, GO enrichment and DoRothEA that estimate pathway and transcription factor (TF) activities, respectively, and compared them against the tools AUCell and metaVIPER, designed for scRNA-seq. For the in silico study we simulated single cells from TF/pathway perturbation bulk RNA-seq experiments. Our simulation strategy guarantees that the information of the original perturbation is preserved while resembling the characteristics of scRNA-seq data. We complemented the in silico data with in vitro scRNA-seq data upon CRISPR-mediated knock-out. Our benchmarks on both the simulated and real data revealed comparable performance to the original bulk data. Additionally, we showed that the TF and pathway activities preserve cell-type specific variability by analysing a mixture sample sequenced with 13 scRNA-seq different protocols. Our analyses suggest that bulk functional genomics tools can be applied to scRNA-seq data, outperforming dedicated single cell tools. Furthermore we provide a benchmark for further methods development by the community.

bioinformatics↗

bioRxiv2019

Stratification and prediction of drug synergy based on target functional similarity

Targeted mono-therapies in cancer are hampered by the ability of tumor cells to escape inhibition through rewiring or alternative pathways. Drug combination approaches can provide a means to overcome these resistance mechanisms. Effective use of combinations requires strategies to select combinations from the enormous space of combinations, and to stratify patients according to their likelihood to respond. We here introduce two complementary workflows: One prioritising experiments in high-throughput screens for drug synergy enrichment, and a consecutive workflow to predict hypothesis-driven synergy stratification. Both approaches only need data of efficacy of single drugs. They rely on the notion of target functional similarity between two target proteins. This notion reflects how similarly effective drugs are on different cancer cells as a function of cancer signaling pathways activities on those cells. Our synergy prediction workflow revealed that two drugs targeting either the same or functionally opposite pathways are more likely to be synergistic. This enables experimental prioritisation in high-throughput screens and supports the notion that synergy can be achieved by either redundant pathway inhibition or targeting independent compensatory mechanisms. We tested the synergy stratification workflow on seven target protein pairs (AKT/EGFR, AKT/MTOR, BCL2/MTOR, EGFR/MTOR, AKT/BCL2, AKT/ALK and AKT/PARP1, representing 29 combinations and predicted their synergies in 33 breast cancer cell lines (Pearsons correlation r=0.27). Additionally, we experimentally validated predicted synergy of the BRAF/Insulin Receptor combination (Dabrafenib/BMS-754807) in 48 colorectal cancer cell lines (r=0.5). In conclusion, our synergy prediction workflow can support compound prioritization in large scale drug screenings, and our synergy stratification workflow can select where the efficacy of drugs already known for inducing synergy is higher.

bioinformatics↗

bioRxiv2019

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening

Many gene fusions have been reported in tumours and for most their role remains unknown. As fusions can be used clinically for diagnostic and prognostic purposes, and are targets for treatment, it is crucial to assess their functional implications in cancer. To investigate the role of fusions in tumor cell fitness, we developed a systematic analysis utilising RNA-sequencing data from 1,011 human cancer cell lines to functionally link 8,354 gene fusion events with genomic data, sensitivity to >350 anti-cancer drugs and CRISPR-Cas9 loss-of-fitness information. Established clinically-relevant fusions were readily identified. Overall, functional fusions were rare, including those involving cancer driver genes, suggesting that many fusions are dispensable for tumor cell fitness. Novel therapeutically actionable fusions involving RAF1, BRD4 and ROS1 were verified in new histologies. In addition, recurrent YAP1-MAML2 fusions were identified as activators of Hippo-pathway signaling in multiple cancer types, supporting therapeutic targeting of Hippo signalling. Our approach discriminates functional fusions, identifying new drivers of carcinogenesis and fusions that could have important clinical implications. SignificanceWe identify fusions as new potential candidates for drug repurposing and drivers of carcinogenesis. These results support histology agnostic marker-driven precision cancer medicine. Most fusions are not functional with implications for interpreting cancer fusions reported from clinical sequencing studies.

cancer biology↗

bioRxiv2019

Prediction of combination therapies based on topological modeling of the immune signaling network in Multiple Sclerosis

Signal transduction deregulation is a hallmark of many complex diseases, including Multiple Sclerosis (MS). Here, we performed ex vivo multiplexed phosphoproteomic assays in PBMCs from 180 MS patients either untreated or treated with fingolimod, natalizumab, interferon-beta, glatiramer acetate or the experimental therapy epigallocatechin gallate (EGCG), and from 60 matched healthy controls. Fitting a bespoke literature-derived network of MS-related pathways using logic modeling yielded a signaling network specific for each patient. Patient models were merged to characterize healthy-, disease- and drug-specific signaling networks. We defined a co-druggability score based on the topology for each drugs network. We used this score to identify kinase interactions whose activity could be reverted to a "healthy-like" status by combination therapy. We predicted several combinations with approved MS drugs. Specifically, TAK1 kinase, involved in TGF-B, toll-like receptor, B-cell receptor and response to inflammation pathways was found to be highly deregulated and co-druggable with four MS drugs. One of these predicted combinations, Fingolimod with a TAK1 inhibitor, was validated in an animal model of MS. Our approach based on patient-specific signaling networks enables prediction of targets for combination therapy for MS and other complex diseases. One sentence summaryA new approach to predict combination therapies based on modeling signaling architecture using phosphoproteomics from patients with Multiple Sclerosis characterizes deregulated signaling pathways and reveals new therapeutic targets and drug combinations.

systems biology↗

bioRxiv2019

From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL

While gene expression profiling is commonly used to gain an overview of cellular processes, the identification of upstream processes that drive expression changes remains a challenge. To address this issue, we introduce CARNIVAL, a causal network building tool which derives network architectures from gene expression footprints. CARNIVAL (CAusal Reasoning pipeline for Network identification using Integer VALue programming) integrates different sources of prior knowledge, including signed and directed protein-protein interactions, transcription factor targets, and pathway signatures. The use of prior knowledge in CARNIVAL allows the capture of a broad set of upstream cellular processes and regulators, which in turn delivered results with higher accuracy when benchmarked against related tools. Implementation as an integer linear programming (ILP) problem also guarantees efficient computation. As a case study, we applied CARNIVAL to contextualize signaling networks from gene expression data in IgA nephropathy, a chronic kidney disease. CARNIVAL identified specific signaling pathways and associated mediators with important bioactivity in IgAN including WNT and TGF-{beta}, that we subsequently validated experimentally. In summary, we demonstrated how CARNIVAL generates hypotheses on potential upstream alterations that propagate through signaling networks, providing valuable insights into disease processes. CARNIVAL, freely available as an R-package at https://saezlab.github.io/CARNIVAL, can be applied to any field of biomedical research to contextualize signaling networks and identify the causal relationships between downstream gene expression and upstream regulators.

systems biology↗

bioRxiv2019

Transfer of regulatory knowledge from human to mouse for functional genomic analysis

Transcriptome profiling followed by differential gene expression analysis often leads to unclear lists of genes which are hard to analyse and interpret. Functional genomic tools are powerful approaches for downstream analysis, as they summarize the large and noisy gene expression space in a smaller number of biological meaningful features. In particular, methods that estimate the activity of processes by mapping transcripts level to process members are popular. However, footprints of either a pathway or transcription factor (TF) on gene expression show superior performance over mapping-based gene sets. These footprints are largely developed for human and their usability in the broadly-used model organism Mus musculus is uncertain. Evolutionary conservation of the gene regulatory system suggests that footprints of human pathways and TFs can functionally characterize mice data. In this paper we analyze this hypothesis. We perform a comprehensive benchmark study exploiting two state-of-the-art footprint methods, DoRothEA and an extended version of PROGENy. These methods infer TF and pathway activity, respectively. Our results show that both can recover mouse perturbations, confirming our hypothesis that footprints are conserved between mice and humans. Subsequently, we illustrate the usability of PROGENy and DoRothEA by recovering pathway/TF-disease associations from newly generated disease sets. Additionally, we provide pathway and TF activity scores for a large collection of human and mouse perturbation and disease experiments (2,374). We believe that this resource, available for interactive exploration and download (https://saezlab.shinyapps.io/footprint_scores/), can have broad applications including the study of diseases and therapeutics.

systems biology↗

bioRxiv2018

Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening

Functional genomics approaches can overcome current limitations that hamper oncology drug development such as lack of robust target identification and clinical efficacy. Here we performed genome-scale CRISPR-Cas9 screens in 204 human cancer cell lines from 12 cancer-types and developed a data-driven framework to prioritise cancer therapeutic candidates. We integrated gene cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritise new oncology targets in defined tissues and genotypes. Furthermore, we took one of our most promising dependencies, Werner syndrome RecQ helicase, and verified it as a candidate target for tumours with microsatellite instability. Our analysis provides a comprehensive resource of cancer dependencies, a framework to prioritise oncology targets, and nominates specific new candidates. The principles described in this study can transform the initial stages of the drug development process contributing to a new, diverse and more effective portfolio of oncology targets.

cancer biology↗

bioRxiv2018

Signatures of cell death and proliferation in perturbation transcriptomics data - from confounding factor to effective prediction

Transcriptomics perturbation signatures are valuable data sources for functional genomic studies. They can be effectively used to identify mechanism of action for new compounds and to infer functional activity of different cellular processes. Linking perturbation signatures to phenotypic studies opens up the possibility to model selected cellular phenotypes from gene expression data and to predict drugs interfering with the phenotype. At the same time, close association of transcriptomics changes with phenotypes can potentially mask the compound specific signatures. By linking perturbation transcriptomics data from the LINCS-L1000 project with cell viability phenotypic information upon genetic (from Achilles project) and chemical (from CTRP screen) perturbations for more than 90,000 signature - cell viability pairs, we show here that a cell death signature is a major factor behind perturbation signatures. We use this relationship to effectively predict cell viability from transcriptomics signatures, and identify and experimentally validate compounds that induce either cell death or proliferation. We also show that cellular toxicity can lead to an unexpected similarity of toxic compound signatures confounding the mechanism of action discovery. Consensus compound signatures predict cell-specific anti-cancer drug sensitivity, even if the drug signature is not measured in the same cell line. These signatures outperform conventional drug-specific features like nominal target and chemical fingerprints. Our results can help removing confounding factors of large scale transcriptomics perturbation screens and show that expression signatures boost prediction of drug sensitivity.

systems biology↗